Cargando…

Outcomes and Treatment Patterns of Adding a Third Agent to 2 OADs in Patients with Type 2 Diabetes

BACKGROUND: Patients with uncontrolled type 2 diabetes mellitus (T2DM), despite therapy with 2 oral antidiabetic drugs (OADs), may add a third OAD or a glucagon-like peptide-1 receptor agonist (GLP-1) or initiate insulin therapy. The transition to insulin has been shown to be delayed in current prac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levin, Philip A., Wei, Wenhui, Zhou, Steve, Xie, Lin, Baser, Onur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438237/ https://www.ncbi.nlm.nih.gov/pubmed/24761822 http://dx.doi.org/10.18553/jmcp.2014.20.5.501

Ejemplares similares

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
por: Desouza, Cyrus, et al.
Publicado: (2020)

Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine
por: Miao, Raymond, et al.
Publicado: (2013)

R(h)oads to microvesicles
por: Antonyak, Marc A., et al.
Publicado: (2012)

Where do conventional OADs stand
por: Sahay, Rakesh Kumar, et al.
Publicado: (2012)

Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs
por: Baser, Onur, et al.
Publicado: (2013)

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
por: Blonde, Lawrence, et al.
Publicado: (2018)

Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study
por: Wang, Li, et al.
Publicado: (2013)

Much Ado About Nothing? A Real-World Study of Patients with Type 2 Diabetes Switching Basal Insulin Analogs
por: Wei, Wenhui, et al.
Publicado: (2014)

A Novel Long Noncoding RNA, Lnc-OAD, Is Required for Bone Morphogenetic Protein 2- (BMP-2-) Induced Osteoblast Differentiation
por: Wang, Zonggui, et al.
Publicado: (2021)

Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes
por: Levin, Philip A., et al.
Publicado: (2015)

Once-Weekly Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10
por: Capehorn, Matthew, et al.
Publicado: (2020)

A real‐world study of treatment patterns and outcomes in US managed‐care patients with type 2 Diabetes initiating injectable therapies
por: Wei, Wenhui, et al.
Publicado: (2017)

Gender Differences in Inhaled Pharmacotherapy Utilization in Patients with Obstructive Airway Diseases (OADs): A Population-Based Study
por: Amegadzie, Joseph Emil, et al.
Publicado: (2020)

Long-Term Treatment with Trazodone Once-A-Day (TzOAD) in Patients with MDD: An Observational, Prospective Study
por: Shrashimirova, Milena, et al.
Publicado: (2023)

Successful outcomes using Long Acting Buprenorphine (LAB - Buvidal) to treat Codeine, Tramadol and other Opioid Analgesia Dependencies (OAD) in Wales during the Pandemic
por: Melichar, J., et al.
Publicado: (2022)

Fabrication and Characteristics of ZnO/OAD-InN/PbPc Hybrid Solar Cells Prepared by Oblique-Angle Deposition
por: Chen, Cheng-Chiang, et al.
Publicado: (2012)

Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data
por: Levin, P, et al.
Publicado: (2015)

Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH
por: Hwang, Anne, et al.
Publicado: (2018)

Use of Open Claims vs Closed Claims in Health Outcomes Research
por: Baser, Onur, et al.
Publicado: (2023)

Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes
por: Yen, Fu-Shun, et al.
Publicado: (2021)

Eating Patterns and Health Outcomes in Patients With Type 2 Diabetes
por: Aguiar Sarmento, Roberta, et al.
Publicado: (2017)

Practical combination therapy based on pathophysiology of type 2 diabetes
por: Levin, Philip A
Publicado: (2016)

Dipeptidyl Peptidase-4 Inhibitors as a Third-Line Oral Antihyperglycaemic Agent in Patients with Type 2 Diabetes Mellitus: The Impact of Ethnicity
por: Zhang, X., et al.
Publicado: (2014)

Population density index and its use for distribution of Covid-19: A case study using Turkish data
por: Baser, Onur
Publicado: (2021)

Generalized Propensity Score Matching with Multilevel Treatment Options
por: Baser, Onur
Publicado: (2013)

Relationship between Body Mass Index and Diagnosis of Overweight or Obesity in Veterans Administration Population
por: Baser, Onur, et al.
Publicado: (2023)

Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary
por: Jermendy, György, et al.
Publicado: (2008)

CORRIGENDUM FOR “Eating Patterns and Health Outcomes in Patients With Type 2 Diabetes”
Publicado: (2018)

The Association between Metformin Use and Risk of Developing Severe Dementia among AD Patients with Type 2 Diabetes
por: Xue, Ying, et al.
Publicado: (2023)

Grecian Athletic Training in the Third Century (A.D.)
por: Gordon, Burgess
Publicado: (1935)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial (STOP‐OB)
por: Kitazawa, Toru, et al.
Publicado: (2020)

Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus
por: Nargesi, Arash A., et al.
Publicado: (2021)

Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada
por: Carney, Greg, et al.
Publicado: (2022)

The Management of Type 2 Diabetic Patients with Hypoglycemic Agents
por: Carnevale Schianca, G. P., et al.
Publicado: (2012)

The Management of Type 2 Diabetic Patients with Hypoglycaemic Agents
por: Tsang, Man-Wo
Publicado: (2012)

Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey
por: Baser, Onur, et al.
Publicado: (2013)

Cytoreductive treatment patterns among US veterans with polycythemia vera
por: Parasuraman, Shreekant, et al.
Publicado: (2018)

Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study
por: KÖSEOĞLU, Derya, et al.
Publicado: (2021)

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
por: Tajima, Naoko, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_var588cvsiqhvm2e5ajtbv5vi2